Hoth Therapeutics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

view original post

The Dow Jones jumped by around 197 points on Monday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.3

Better Therapeutics

  • The Trade: Better Therapeutics, Inc. BTTX 10% owner David P. Perry 2015 Trust bought a total of 50,000 shares at an average price of $2.05. To acquire these shares, it cost around $102.6 thousand.
  • What’s Happening: Better Therapeutics, last month, reported Q2 2022 R&D expenses of $4.2 million.
  • What Better Therapeutics Does: Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases.

Cardiff Oncology

  • The Trade: Cardiff Oncology, Inc. CRDF Director Gary Pace acquired a total of 150,000 shares at an average price of $1.71. The insider spent around $256.5 thousand to buy those shares.
  • What’s Happening: Cardiff Oncology recently said it will not independently fund any future clinical activities in metastatic castrate-resistant prostate cancer.
  • What Cardiff Oncology Does: Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Dow, Nasdaq Futures Lower Ahead Of Fed Meeting

Don’t forget to check out our premarket coverage here .

Hoth Therapeutics

  • The Trade: Hoth Therapeutics, Inc. HOTH CEO and President Robb Knie acquired a total of 10,000 shares at an average price of $0.40. To acquire these shares, it cost around $4 thousand.
  • What’s Happening: Hoth Therapeutics mRNA frame-shifting therapeutic, HT-004, recently showed potential to reduce lung inflammation in asthma and allergy disorders.
  • What Hoth Therapeutics Does: Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne.

Venus Concept

  • The Trade: Venus Concept Inc. VERO CFO Domenic della Penna acquired a total of 60,000 shares at an average price of $0.59. The insider spent $35.4 thousand to buy those shares.
  • What’s Happening: Venus Concept, last month, posted a Q2 loss of $0.16 per share.
  • What Venus Concept Does: Venus Concept Inc is a medical technology company. It develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services.

Related Posts